Abstract
With great interest we read the report by Annane and colleagues describing the effect of blocking complement factor C5 with the antibody eculizumab in patients with severe COVID-19 [1]. Results of this non-controlled study show an important proof of principle of complement inhibition therapy in patients with severe COVID-19. Increasing evidence point towards a critical role of the proinflammatory anaphylatoxin C5a in the pathogenesis of severe COVID-19 [2–4]. A previous study showed that controlling the anaphylatoxin C5a in disease requires a specifically targeted inhibition [5].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
